Solana has returned to the spotlight after the SuperTrend indicator on its three-day chart flashed a buy signal, accompanied by positive RSI divergence in higher timeframes. Analysts say that if SOL can hold above its recent lows and attract new buyers, the price could open up space to target the $100 level.
SuperTrend indicator signals buy opportunity for Solana as analysts eye $100 level
Shift in trend appears on the three-day chart
For the first time since October 10, the SuperTrend indicator on Solana’s three-day chart has issued a buy signal. This technical shift comes after a period of sharp correction, suggesting that selling pressure in the market structure may be fading and buyers could be regaining strength.
In a chart shared by Ali Charts, Solana’s attempt at recovery after a prolonged downtrend has gained attention. The signal line of the SuperTrend moving below the current price is typically interpreted by technical analysts as the initial sign of buyers reclaiming momentum in the asset.
Mini glossary: The SuperTrend indicator is used to track the direction of price movements and potential support-resistance areas. ATR, or Average True Range, measures price volatility, and SuperTrend uses this data to dynamically determine stop levels.
Ali Charts has emphasized that this is the first SuperTrend buy signal for SOL since October 10, highlighting the need for closer monitoring compared to prior months.
Following the previous sell signal, Solana’s price dropped 74%. For this reason, the indicator’s switch back to a bullish signal carries particular technical significance. Yet, analysts caution that this alone isn’t sufficient; for an upward move to be sustained, SOL must remain above its new support zone.
The key threshold in the short term stands at $100. If SOL can hold this structure and strengthen its upward momentum, the market could retest this region. On the other hand, slipping below the new support would weaken the positive outlook.
Weekly chart reveals bullish RSI divergence
Zooming out to higher timeframes, TraderJB suggests that Solana may be entering the final stages of its corrective phase. According to the Elliott Wave structure on the weekly chart, after the primary rally that began in 2023, a classic peak formation developed, followed by an A-B-C correction.
TraderJB points out that during previous waves 3 and 5 tops, negative RSI divergence was observed—a technical pattern typically indicating rising risk of a top as price increases while momentum weakens. Now, toward the end of the current C wave, the pattern appears to be reversing.
The chart highlights positive RSI divergence around the minor waves 3 and 5 within the C wave. According to analysts, this suggests that selling pressure may be easing, potentially turning the current zone into an accumulation area, especially for longer-term investors.
TraderJB notes that if the wave count remains valid, the current region offers a compelling risk-reward profile for spot accumulation, provided that SOL manages to defend its recent lows.
Nevertheless, further confirmation is required before a broader trend reversal can be declared. Should Solana protect its recent lows while decisively building upward momentum, the scenario for a more substantial recovery may strengthen.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

